Free Trial

Johnson & Johnson (JNJ) Stock Forecast & Price Target

$152.33
-1.91 (-1.24%)
(As of 07/23/2024 ET)

Johnson & Johnson - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 13 Wall Street analysts who have issued ratings for Johnson & Johnson in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 7 have given a hold rating, and 6 have given a buy rating for JNJ.

Consensus Price Target

$173.00
13.57% Upside
High Forecast$215.00
Average Forecast$173.00
Low Forecast$150.00

According to the 13 analysts' twelve-month price targets for Johnson & Johnson, the average price target is $173.00. The highest price target for JNJ is $215.00, while the lowest price target for JNJ is $150.00. The average price target represents a forecasted upside of 13.57% from the current price of $152.33.

TypeCurrent Forecast
7/24/23 to 7/23/24
1 Month Ago
6/24/23 to 6/23/24
3 Months Ago
4/25/23 to 4/24/24
1 Year Ago
7/24/22 to 7/24/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
4 Buy rating(s)
Hold
7 Hold rating(s)
8 Hold rating(s)
7 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$173.00$174.07$175.86$171.60
Forecasted Upside13.57% Upside12.39% Upside13.00% Upside4.44% Upside
Get Johnson & Johnson Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.

JNJ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

JNJ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Johnson & Johnson Stock vs. The Competition

TypeJohnson & JohnsonMedical CompaniesS&P 500
Consensus Rating Score
2.46
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside13.26% Upside3,082.09% Upside9.39% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/23/2024Daiwa Capital Markets
1 of 5 stars
 DowngradeOutperform ➝ Neutral$160.00 ➝ $150.00-2.75%
7/19/2024The Goldman Sachs Group
2 of 5 stars
 Lower TargetNeutral ➝ Neutral$160.00 ➝ $155.00+0.27%
7/18/2024Sanford C. Bernstein
3 of 5 stars
 Boost Target$161.00 ➝ $171.00+9.10%
7/18/2024TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$195.00 ➝ $185.00+18.03%
7/18/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$195.00 ➝ $185.00+18.38%
7/18/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$175.00 ➝ $175.00+11.93%
7/18/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$167.00 ➝ $169.00+7.93%
7/1/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00+45.14%
4/18/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$169.00 ➝ $170.00+17.43%
4/17/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$180.00 ➝ $170.00+17.96%
1/3/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$172.00 ➝ $175.00+8.93%
12/13/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$170.00 ➝ $163.00+5.11%
12/1/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$167.00 ➝ $180.00+16.39%
10/12/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$158.00 ➝ $162.00+3.73%
8/4/2023Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$167.00 ➝ $170.00-0.42%
7/21/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$175.00 ➝ $180.00+5.75%
7/21/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$165.00 ➝ $175.00+3.92%
7/21/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$170.00 ➝ $175.00+3.92%
5/30/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$185.00+19.86%
2/28/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$161.00+5.05%
2/6/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$55.00 ➝ $52.00-68.17%
1/20/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$194.00 ➝ $186.00+9.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 08:46 PM ET.

JNJ Forecast - Frequently Asked Questions

What is Johnson & Johnson's forecast for 2024?

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Johnson & Johnson is $173.00, with a high forecast of $215.00 and a low forecast of $150.00.

Should I buy or sell Johnson & Johnson stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last twelve months. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" JNJ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JNJ, but not buy additional shares or sell existing shares.

Does Johnson & Johnson's stock price have much upside?

According to analysts, Johnson & Johnson's stock has a predicted upside of 11.66% based on their 12-month stock forecasts.

Has Johnson & Johnson been downgraded by Wall Street analysts recently?

Over the previous 90 days, Johnson & Johnson's stock had 1 downgrade by analysts.

What analysts cover Johnson & Johnson?

Johnson & Johnson has been rated by research analysts at Cantor Fitzgerald, Daiwa Capital Markets, Morgan Stanley, Royal Bank of Canada, Sanford C. Bernstein, TD Cowen, TD Securities, and The Goldman Sachs Group in the past 90 days.

Do Wall Street analysts like Johnson & Johnson more than its competitors?

Analysts like Johnson & Johnson less than other "medical" companies. The consensus rating for Johnson & Johnson is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how JNJ compares to other companies.


This page (NYSE:JNJ) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners